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Background. Serum procalcitonin (PCT) is a useful biomarker to tailor the duration of antibiotics in respiratory infections. The
objective of this study was to determine whether PCT levels could tailor postoperative antibiotic therapy in patients operated
for peritonitis. Method. Patients with peritonitis were randomized postoperatively. The control group received antibiotics for a
deﬁned duration according to institutional guidelines. In the study group, antibiotics were stopped based on serum PCT levels.
Patients were stratiﬁed into three categories: (1) gastrointestinal perforation, (2) perforated appendicitis, and (3) postoperative
complication. Primary outcome was duration of antibiotics. Results. We included 162 patients: 83 and 79 patients in the
control group and study group, respectively. In the subgroup of patients with peritonitis due to gastrointestinal perforation, we
found 7 days of antibiotics in the PCT group versus 10 days in the control group (p value 0.065). There was no diﬀerence in
infectious complications, mortality, median length of hospital stay, and necessity to restart antibiotics. Conclusion. No
signiﬁcant diﬀerences were found in duration of antibiotics when applying PCT guidance. However, in the subgroup of
primary perforation of the gastrointestinal tract, there was a diﬀerence in duration of antibiotics in favor of the PCT group
without obtaining signiﬁcance, as the study was not powered for subgroup analysis. Further studies including only this
subgroup should be performed.
1. Introduction
Successful management of peritonitis due to perforation of
the gastrointestinal tract remains challenging, even in the
era of modern surgery. Incidences of infectious and nonin-
fectious complications remain high, as is the mortality rate
[1]. Rapid diagnosis, eﬃcient surgical intervention, and
potent antibiotics are the most relevant cornerstones of any
treatment algorithm. Perioperative broad spectrum antibi-
otics are commonly used, allowing clearance of aerobic and
anaerobic bacteria. While antibiotics are empirically targeted
at the usual digestive ﬂora, there is poor consensus on the
duration of antibiotic treatment, and most institutions have
adopted their own guidelines. Nevertheless, appropriate
shortening of the treatment duration may be a crucial aspect
limiting antibiotic resistance, costs, duration of hospital stay,
and improving patient’s outcomes [2].
The use of biomarkers to assess the treatment eﬃcacy on
infections is commonly known, but a speciﬁc parameter to
monitor the duration of antibiotics has been lacking. Procal-
citonin (PCT), a precursor of calcitonin, is ampliﬁed as part
of the physical response to bacterial infections [3, 4]. In ani-
mal models as well as in clinical settings, the correlation of
PCT and the severity of sepsis have been shown to be supe-
rior to other biological markers, such as C-reactive protein,
interleukin-1, or interleukin-6 [4–6]. Furthermore, there is
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solid evidence that the treatment of community-acquired
pneumonia and ventilator-associated pneumonia can eﬀec-
tively be monitored by repeated measurement of serum
PCT levels, and the duration of antibiotics can signiﬁcantly
be shortened [7–11]. Therefore, we hypothesized that the
duration of antibiotic treatments based on current guidelines
represents an “overtreatment,” and a tailored approach could
shorten antibiotic therapy without increasing infectious
complications in patients with gastrointestinal perforations.
The aim of this study was to assess the usefulness of PCT
to guide the duration of antibiotic use in surgical patients
with peritonitis due to gastrointestinal perforation.
2. Patients and Methods
2.1. Setting and Study Population. The current study is a
prospective randomized trial performed at a university
hospital. The duration of antibiotic therapy in patients
treated according to institution guidelines with deﬁned anti-
biotic duration (control group, Table 1) was compared to
patients in whom antibiotic treatment was guided by serum
PCT levels (procalcitonin (PCT) group). The study protocol
was approved by the local ethical committee, registered
(www.clinicaltrials.gov, NCT01155739), and all patients gave
written informed consent.
2.2. Inclusion Criteria. All patients > 18 years who underwent
abdominal surgery and with an established diagnosis of peri-
tonitis were potentially eligible. All types of peritonitis caused
by gastrointestinal perforations were included (gastric, puru-
lent, fecal, or ﬁbrinous content) either restricted to one quad-
rant or generalized to all four quadrants. After inclusion into
the study, patients were stratiﬁed into three categories based
upon the diagnosis: (1) peritonitis related to a gastrointesti-
nal perforation (e.g., diverticulitis, perforated gastric or duo-
denal ulcer, intestinal ischemia, iatrogenous perforation,
intestinal perforation in trauma patients, and perforated
malignancy), (2) peritonitis due to perforated appendicitis,
and (3) peritonitis due to a postoperative complication.
2.3. Exclusion Criteria. Patients with any kind of immuno-
suppression (e.g., long-term corticosteroids, chemotherapy,
organ transplantation, and HIV with <200 CD4 cells),
patients with medullary cancer of the thyroid or severe hepa-
tocellular insuﬃciency (high procalcitonin values), and spon-
taneous peritonitis in patients with ascites were excluded. In
addition, patients who refused to sign informed consent were
not included.
2.4. Study Intervention and Randomization. Inclusion of
patients was done postoperatively, after the diagnosis of peri-
tonitis was established and its origin determined by surgery.
Patients were randomly assigned to the control or PCT group
through sealed, opaque envelopes. There was no stratiﬁcation
of randomization based on the three subgroups. Randomiza-
tion was blinded for the patient, while physicians were aware
of the respective group. In both groups, empiric antibiotic
therapy was started preoperatively or at induction of anesthe-
sia, and serum PCT levels were determined at the day of sur-
gery or postoperative day 1. In the control group, duration of
antibiotic application was according to institutional guide-
lines (Table 1), but of note, duration was prolonged if clini-
cally indicated, for example, in case of persisting fever,
increasing infectious laboratory values, or infectious compli-
cations (abscess, positive blood cultures).
In the PCT group, antibiotics were continued until post-
operative day 3, without consideration of the respective
serum PCT levels. On the third postoperative day, serum
PCT values were measured and antibiotics were stopped if
serum PCT values < 1 μg/l; if values were >1μg/l, antibiotics
were continued. Serum PCT values were determined every
following 48 h, and in case of serum PCT values < 0 25 μg/l
or a decrease of 80% compared to the baseline value, anti-
biotics were then stopped. The daily physical examination
of the patient was taken into account when stopping the
antibiotics. In case of a clinical suspicion of an ongoing
infection, antibiotics could be kept or reintroduced inde-
pendently of the respective serum PCT levels or other
diagnostic measures.
2.5. Measurement of PCT. Serum PCT measurements were
performed with the Electrochemiluminescence immunoas-
say (ECLIA) on the automated Roche Elecsys® immunoassay
analyzers and were obtained in approximately two hours.
2.6. Outcome Measures. The primary outcome measure was
the duration of antibiotics in days. This includes the initial
treatment, until discontinuation of antibiotics. If antibiotics
were restarted, this was not included in the duration of anti-
biotics. Secondary outcome measures were (1) duration of
hospitalization, (2) incidence of 30-day infectious complica-
tions, (3) 30-day mortality, and (4) incidence of reintroduc-
tion of antibiotics after having been ceased.
Table 1: Institutional guidelines for duration of antibiotic therapy, based on the Surgical Infection Society guidelines [15–17].
Indication Duration First choice antibiotics
Perforated appendicitis with peritonitis 5 days
Amoxicillin/clavulanic acid
Allergy: ciproﬂoxacin +metronidazole
Peritonitis due to gastrointestinal perforation 10 days
Amoxicillin/clavulanic acid. If severe infection:
imipenem or piperacillin/tazobactam
Allergy: ciproﬂoxacin +metronidazole
Peritonitis due to gastrointestinal perforation,
acquired in-hospital
10 days
Imipenem or piperacillin/tazobactam
Allergy: ciproﬂoxacin +metronidazole
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To compare groups, age, gender, comorbidities, ASA
score, and Mannheim Peritonitis Index [12] were docu-
mented in all patients.
2.7. Statistical Analysis. The sample size was calculated based
on a 33% reduction in antibiotic duration (10 days in control
group, 6.7 days in study group, standard deviation 7.55 days).
With a power of 80% and an α-error of 0.05 using a two-
tailed test, 166 patients (83 per group) were necessary.
Categorical data are presented as numbers with percent-
ages; numerical data are presented as medians with inter-
quartile ranges. Univariate analysis was performed using a
Fisher’s exact test in case of categorical data, and a Mann–
Whitney U test in case of numerical data. Data were analyzed
as intention-to-treat. Statistical analysis was performed with
SPSS version 22.
3. Results
From June 2009 to September 2012, 162 patients with perito-
nitis were included and randomized between procalcitonin
and control groups (CONSORT diagram Figure 1). Due to
dropouts after initial inclusion, the power calculation was
initially not obtained and the 10 last were included end
2013–beginning 2014 for this reason.
The baseline characteristics of all patients are shown in
Table 2. There were 64 patients in the group with peritonitis
related to a gastrointestinal perforation (group 1), 73
patients with peritonitis due to acute appendicitis (group
2), and 25 patients with peritonitis due to a postoperative
complication (group 3).
The overall mortality rate was 4.3%, whereby these
patients had a signiﬁcant higher Mannheim Peritonitis Index
(median 29 (range 23–34) versus median 17 (11.75–24),
p value 0.005).
3.1. Primary Endpoint. When comparing all patients, there
was no diﬀerence in duration of antibiotics between the
PCT and control group (Table 3). The results for the sub-
group analysis for patients with peritonitis related to a gas-
trointestinal perforation (group 1) separately show a trend
towards a reduced duration of antibiotics in the PCT arm,
without obtaining signiﬁcance (median 7 versus 10 days,
p value 0.065, Table 3).
3.2. Secondary Endpoints. There were no signiﬁcant diﬀer-
ences in infectious complications or death, as depicted in
Table 4. Median duration of hospital stay was similar
between both groups. Results of the secondary endpoints
are shown for all patients together and for the subgroup anal-
ysis of group 1 separately since this group had a trend for sig-
niﬁcant diﬀerence for the primary endpoint.
Figure 2 shows the relation of the initial level of procalci-
tonin to later complications. The median level of the initial
PCT value (on day of surgery or the next day) in the group
with no further complications was 2.2μg/l (interquartile
range 0.5–7.5), whereas it was 4.6μg/l (interquartile range
1.3–14.7) in the group having one or more infectious compli-
cations in the postoperative phase. A Mann–Whitney U
test shows that this diﬀerence is statistically diﬀerent with
a p value of 0.07.
Figure 3 shows the scatter plot of the initial level of pro-
calcitonin to needed duration of antibiotic therapy. The
Spearman’s rank correlation coeﬃcient is r = 0 4, with a
p value > 0.01.
4. Discussion
This randomized controlled study assessed the role of a prede-
ﬁned algorithm using serum PCT levels to tailor the duration
antibiotic therapies after surgery for peritonitis. To this end,
162 patient were randomized to receive either a PCT-guided
therapy or a standard antibiotic treatment according to insti-
tutional guidelines. The main ﬁnding was that there were no
diﬀerences of the duration of antibiotic treatment between
both groups. In patients with an already short antibiotic treat-
ment, for example, localized peritonitis after appendicitis, the
algorithm failed to further shorten the duration of antibiotic
use. Patients with peritonitis due to a postoperative complica-
tion (mostly anastomotic leakages) revealed the longest antibi-
otic therapies, but no reduction was achieved using the PCT
algorithm. However, patients admitted to the hospital with
peritonitis caused by primary gastrointestinal perforations
were apt to the PCT algorithm, with a decreased median
length of antibiotic treatment of three days, without obtaining
statistical signiﬁcance. This study was not powered for sub-
group analysis; we speculate that no statistical signiﬁcance
was obtained due to insuﬃcient power (type II error) due to
a small patient subgroup. Further analysis of this subgroup
showed no increased rate of infectious complications in the
shorted antibiotics group compared to patients with a pro-
longed standard treatment time. The shortening of the antibi-
otic treatment duration may be a crucial aspect limiting
antibiotic resistance, costs, duration of hospital stay, and
improving patient’s outcomes in this subgroup.
Interestingly, a higher initial value of PCT on postopera-
tive day 0 or 1 seems to have a relation with a longer duration
of antibiotic therapy and gives a higher risk of postoperative
infectious complications.
This study was based on the positive results obtained with
PCT guidance in pneumonia. Randomized controlled studies
were set up in patients with suspicion of community-
acquired pneumonia, and PCT values were used to initiate
and to the duration of antibiotics [7, 8]. Initiation and
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(i)
Allocated to control
Assessed for eligibility
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(n =79)
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Figure 1: CONSORT diagram of included patients.
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Table 2: Baseline characteristics.
Procalcitonin group
(n= 79)
Control group
(n= 83)
p value
Median age (range), years 56 (36–73) 57 (36–71) 0.776
Males, n (%) 46 (58.2%) 47 (57%) 0.875
ASA 1-2, n (%) 46 (58.2%) 60 (72.3%)
0.07
ASA 3-4 33 (41.8%) 23 (27.7%)
Comorbidities, n (%)
(i) Diabetes mellitus 4 (5.1%) 4 (4.8%) 1.00
(ii) Pulmonary 13 (16.5%) 7 (8.4%) 0.15
(iii) Cardiac 29 (36.7%) 34 (41%) 0.63
(iv) Renal dysfunction 9 (11.4%) 8 (9.6%) 0.80
Needing ICU hospitalization, n (%) 10 (12.7%) 10 (12.0%) 1.00
Mannheim Peritonitis score (points)
(i) All 19 (11–25) 17 (12–26)
1.00
(ii) Subgroup 1 20 (16–26) 21 (15.5–27.5)
(iii) Subgroup 2 15 (10.8–21.3) 15 (10–21)
(iv) Subgroup 3 24.5 (17.8–29) 28 (21–38)
Peritonitis
0.91
(i) Trouble exsudat 5 (6.3%) 7 (8.4%)
(ii) Gastric/duodenal content 4 (5.1%) 5 (6.0%)
(iii) Fibrinous 3 (3.8%) 3 (3.6%)
(iv) Purulent 53 (67.1%) 52 (62.7%)
(v) Fecal 14 (17.7%) 16 (19.3%)
Peritonitis quadrants
0.73
1 33 (41.8%) 28 (33.7%)
2 10 (12.7%) 14 (16.7%)
3 3 (3.8%) 2 (2.4%)
4 33 (41.8%) 39 (47.0%)
Group 1 peritonitis due to GI perforation 31 33
0.95
(i) Diverticulitis 14 9
(ii) Perforated ulcer 4 11
(iii) Perforation stent/colonoscopy/biopsy 6 5
(iv) Ischemia–necrosis 6 2
(v) High-velocity trauma 0 2
(vi) Perforated tumor 1 1
(vii) Other 0 3
Group 2 peritonitis due to appendicitis 34 39 0.61
Group 3 postoperative peritonitis 14 11
0.43
(i) Anastomotic leakage 6 5
ASA: American Society of Anesthesiologists physical status classiﬁcation system; ICU: intensive care unit.
Table 3: Primary outcome measure: duration of antibiotics (median with interquartile range, days).
Duration antibiotic treatment
Procalcitonin
(n= 79)
Control
(n= 83)
p value
(i) All patients 8 (5–16) 10 (6–12) 0.714
(ii) Subgroup 1: GI perforation 7 (5–12) 10 (8.5–12) 0.065
(iii) Subgroup 2: appendicitis 8 (5.5–13.5) 8 (5–11) 0.573
(iv) Subgroup 3: postoperative 18.5 (6.75–29.5) 13 (11–18) 0.403
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duration was discouraged when ﬁnding PCT values less than
0.25μg/l and encouraged when greater than 0.25μg/l. These
randomized studies showed that prescription of antibiotics
on admission, total antibiotic exposure, and duration of
antibiotic treatment was reduced in the PCT guidance
group, compared with patients treated according to con-
ventional guidelines. Corresponding results were obtained
in ventilator-acquired pneumonia for the duration of anti-
biotics [9].
Our results are in line with the study by Huang et al. who
performed a case-control study using a PCT algorithm to
stop antibiotics in patients with secondary peritonitis [13].
They also showed a reduction of duration of antibiotic
treatment by a median of 3 days, without observing an
increased rate of adverse events. Another study on PCT after
colorectal surgery found that PCT < 1 5 ng/ml on postopera-
tive days 1 to 3 had a strong negative predictive value for sys-
temic infectious complications [14].
There are some limitations of the current study that
should be addressed. First, the duration of antibiotic treatment
for peritonitis is not internationally standardized. Second,
since an algorithm for discontinuation of antibiotics cannot
completely replace clinical patient evaluations, treating physi-
cians could violate the algorithm when clinically suspecting
the need to continue antibiotic treatment. Last, the complete
analysis is concordant with the prestudy power calculation
Table 4: Secondary outcome measures.
Procalcitonin Control p value
All
(n= 79)
Subgroup 1 (n= 31)
All
(n= 83)
Subgroup 1 (n= 33) All Subgroup 1
Duration of hospitalization, d 10 (5–24) 10 (6–24) 8 (4–16) 10 (6–20) 0.188 0.809
Reintroduction of antibiotics 6 (7.7%) 3 (10%) 5 (6.1%) 1 (3%) 0.762 0.340
Reoperation 24 (30.4%) 6 (19.4%) 20 (24.1%) 7 (21.1%) 0.383 1.00
Relavage abdominal cavity 10 (12.7%) 2 (6.5%) 7 (8.4%) 3 (9.1%) 0.447 1.00
Rehospitalization 5 (6.6%) 1 (3.6%) 5 (6.1%) 2 (6.1%) 1.00 1.00
Positive blood cultures 2 (2.5%) 0 3 (3.6%) 2 (6.1%) 1.00 0.493
Intra-abdominal abscess 14 (17.7%) 3 (9.7%) 14 (16.9%) 3 (9.1%) 1.00 1.00
Wound infection 17 (21.5%) 7 (22.6%) 15 (18.1%) 11 (33.3%) 0.694 0.410
Septic shock 4 (5.1%) 1 (3.2%) 4 (4.8%) 3 (9.1%) 1.00 0.614
Anastomotic leakage 3 (3.8%) 1 (3.2%) 3 (3.6%) 2 (6.1%) 1.00 1.00
Urinary infection 3 (3.8%) 2 (6.5%) 1 (1.2%) 0 0.358 0.231
Pneumonia 2 (2.5%) 0 4 (4.8%) 3 (9.1%) 0.682 0.239
Mortality 3 (3.8%) 3 (9.7%) 4 (4.9%) 3 (9.4%) 1.00 1.00
Duration of antibiotics and duration of hospitalization are medians with interquartile range (days). All other parameters are numbers with percentages.
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Figure 2: Relation initial PCT value and the occurring of
postoperative infectious complications. x-axis shows the group of
patients with (yes) and without (no) an infectious postoperative
complication. y-axis shows the median PCT value on day of
surgery or postoperative day 1 in μg/l (error bars 95% CI).
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Figure 3: Relation initial PCT value and postoperative antibiotic
therapy. Scatter plot of duration of antibiotic therapy in days
on x-axis versus the median PCT value on day of surgery or
postoperative day 1 in μg/l. Spearman’s rank correlation
coeﬃcient r = 0 4, with a p value > 0.01.
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but seems to include a too large variety of origins of peritonitis
making the variance of duration of antibiotics too large for sta-
tistical signiﬁcance. A subgroup analysis of a homogeneous
group of patients approaches a level of signiﬁcance without
obtaining a statistical diﬀerence between groups. Since these
are the results of a subgroup analysis, the lack of signiﬁcance
can be explained by a lower number of patients in the sub-
group as anticipated.
In conclusion, a PCT algorithm could be used to guide
antibiotic treatment in case of gastrointestinal perforation
and allows a potential reduction in antibiotic duration. In
particular, patients admitted with primary perforation of
the GI tract may represent a suitable patient target group,
whereas patients with an a priori limited time of antibiotic
treatment do not beneﬁt.
Conflicts of Interest
The authors declare that there is no conﬂict of interest
regarding the publication of this paper.
References
[1] C. Brun-Buisson, F. Doyon, J. Carlet et al., “Incidence, risk fac-
tors, and outcome of severe sepsis and septic shock in adults. A
multicenter prospective study in intensive care units. French
ICU Group for severe sepsis,” Journal of the American Medical
Association, vol. 274, no. 12, pp. 968–974, 1995.
[2] C. Nathan and O. Cars, “Antibiotic resistance—problems,
progress, and prospects,” The New England Journal of Medi-
cine., vol. 371, no. 19, pp. 1761–1763, 2014.
[3] K. L. Becker, E. S. Nylen, J. C. White, B. Muller, and R. H.
Snider Jr., “Clinical review 167: procalcitonin and the calci-
tonin gene family of peptides in inﬂammation, infection,
and sepsis: a journey from calcitonin back to its precur-
sors,” The Journal of Clinical Endocrinology and Metabo-
lism, vol. 89, no. 4, pp. 1512–1525, 2004.
[4] P. Schuetz, M. Christ-Crain, and B. Muller, “Biomarkers to
improve diagnostic and prognostic accuracy in systemic infec-
tions,” Current Opinion in Critical Care, vol. 13, no. 5, pp. 578–
585, 2007.
[5] C. Clec'h, F. Ferriere, P. Karoubi et al., “Diagnostic and prog-
nostic value of procalcitonin in patients with septic shock,”
Critical Care Medicine, vol. 32, no. 5, pp. 1166–1169, 2004.
[6] S. Harbarth, K. Holeckova, C. Froidevaux et al., “Diagnostic
value of procalcitonin, interleukin-6, and interleukin-8 in crit-
ically ill patients admitted with suspected sepsis,” American
Journal of Respiratory and Critical Care Medicine, vol. 164,
no. 3, pp. 396–402, 2001.
[7] M. Christ-Crain, D. Stolz, R. Bingisser et al., “Procalcitonin
guidance of antibiotic therapy in community-acquired pneu-
monia: a randomized trial,” American Journal of Respiratory
and Critical Care Medicine, vol. 174, no. 1, pp. 84–93, 2006.
[8] W. Long, X. Deng, Y. Zhang, G. Lu, J. Xie, and J. Tang, “Pro-
calcitonin guidance for reduction of antibiotic use in low-risk
outpatients with community-acquired pneumonia,” Respirol-
ogy, vol. 16, no. 5, pp. 819–824, 2011.
[9] D. Stolz, N. Smyrnios, P. Eggimann et al., “Procalcitonin for
reduced antibiotic exposure in ventilator-associated pneumo-
nia: a randomised study,” The European Respiratory Journal,
vol. 34, no. 6, pp. 1364–1375, 2009.
[10] L. Bouadma, C. E. Luyt, F. Tubach et al., “Use of procalcitonin
to reduce patients’ exposure to antibiotics in intensive care
units (PRORATA trial): a multicentre randomised controlled
trial,” Lancet, vol. 375, no. 9713, pp. 463–474, 2010.
[11] P. Schuetz, B. Müller, M. Christ-Crain et al., “Procalcitonin to
initiate or discontinue antibiotics in acute respiratory tract
infections,” The Cochrane Database of Systematic Reviews,
vol. 9, no. 4, CD007498, pp. 1297–1371, 2012.
[12] M. M. Linder, H. Wacha, U. Feldmann, G. Wesch, R. A.
Streifensand, and E. Gundlach, “The Mannheim peritonitis
index. An instrument for the intraoperative prognosis of
peritonitis,” Zeitschrift fur Alle Gebiete der Operativen Med-
izen, vol. 58, no. 2, pp. 84–92, 1987.
[13] T. S. Huang, S. S. Huang, Y. C. Shyu et al., “A procalcitonin-
based algorithm to guide antibiotic therapy in secondary peri-
tonitis following emergency surgery: a prospective study with
propensity score matching analysis,” PloS One, vol. 9, no. 3,
article e90539, 2014.
[14] A. M. Chromik, F. Endter, W. Uhl, A. Thiede, H. B. Reith,
and U. Mittelkotter, “Pre-emptive antibiotic treatment vs
'standard' treatment in patients with elevated serum procal-
citonin levels after elective colorectal surgery: a prospective
randomised pilot study,” Langenbeck's Archives of Surgery-
Deutsche Gesellschaft fur Chirurgie, vol. 391, no. 3,
pp. 187–194, 2006.
[15] J. S. Solomkin, J. E. Mazuski, J. S. Bradley et al., “Diagnosis and
management of complicated intra-abdominal infection in
adults and children: guidelines by the surgical infection Society
and the Infectious Diseases Society of America,” Clinical Infec-
tious Diseases, vol. 50, no. 2, pp. 133–164, 2010.
[16] J. E. Mazuski, R. G. Sawyer, A. B. Nathens et al., “The surgical
infection Society guidelines on antimicrobial therapy for intra-
abdominal infections: evidence for the recommendations,”
Surgical Infections., vol. 3, no. 3, pp. 175–233, 2002.
[17] J. E. Mazuski, R. G. Sawyer, A. B. Nathens et al., “The surgical
infection Society guidelines on antimicrobial therapy for
intra-abdominal infections: an executive summary,” Surgical
Infections, vol. 3, no. 3, pp. 161–173, 2002.
6 Gastroenterology Research and Practice
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
